December 2025 in “Cell Communication and Signaling” This study discovered that minoxidil affects hematopoiesis by downregulating wnt4, leading to suppression of hematopoietic stem and progenitor cells and alleviating MDS-like symptoms in zebrafish and mice, with hematologic safety achieved at optimized doses.
This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.
30 citations
,
January 2007 This article reviews the use of cyclophosphamide in kidney disease treatment, highlighting significant concerns about long-term risks of cancer and infertility, and stress strategies for dose reduction and side effect mitigation; no new study results are presented.
January 2025 in “HemaSphere” This review discusses the implications of renaming myelodysplastic syndromes as "myelodysplastic neoplasms" and argues that the "low-risk" label may misrepresent patient experiences and hinder research.
11 citations
,
January 2009 in “World Journal of Gastroenterology” This study reports the first documented case of Cronkhite-Canada syndrome in a patient with myelodysplastic syndrome, where corticosteroids dramatically improved the patient's condition.